{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T09:52:34Z","timestamp":1768643554476,"version":"3.49.0"},"reference-count":115,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T00:00:00Z","timestamp":1662940800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.jinf.2022.09.001","type":"journal-article","created":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T11:24:39Z","timestamp":1662549879000},"page":"481-491","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Public health perspective of a pentavalent meningococcal vaccine combining antigens of MenACWY-CRM and 4CMenB"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0683-6055","authenticated-orcid":false,"given":"Rafik","family":"Bekkat-Berkani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Fragapane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Preiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rino","family":"Rappuoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Woo-Yun","family":"Sohn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lamine","family":"Soumahoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kumaran","family":"Vadivelu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Rr-2","key":"10.1016\/j.jinf.2022.09.001_bib0001","first-page":"1","article-title":"Prevention and control of meningococcal disease: recommendations of the advisory committee on immunization practices (ACIP)","volume":"62","author":"Cohn","year":"2013","journal-title":"MMWR Recomm Rep"},{"issue":"10","key":"10.1016\/j.jinf.2022.09.001_bib0002","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms8101521","article-title":"Vaccines against meningococcal diseases","volume":"8","author":"Pizza","year":"2020","journal-title":"Microorganisms"},{"issue":"21","key":"10.1016\/j.jinf.2022.09.001_bib0003","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1016\/j.vaccine.2019.04.020","article-title":"Case fatality rates of invasive meningococcal disease by serogroup and age: a systematic review and meta-analysis","volume":"37","author":"Wang","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.jinf.2022.09.001_bib0004","unstructured":"American Academy of Pediatrics. Red Book: 2015 Report of the Committee on Infectious Diseases."},{"issue":"1","key":"10.1016\/j.jinf.2022.09.001_bib0005","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1478-7954-11-17","article-title":"Global epidemiology of invasive meningococcal disease","volume":"11","author":"Jafri","year":"2013","journal-title":"Popul Health Metr"},{"key":"10.1016\/j.jinf.2022.09.001_bib0006","unstructured":"World Health Organisation Initiatives. Defeating meningitis by 2030. Available at: https:\/\/www.who.int\/initiatives\/defeating-meningitis-by-2030 (accessed 28 February, 2022)."},{"key":"10.1016\/j.jinf.2022.09.001_bib0007","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2147\/IDR.S21545","article-title":"Meningococcal conjugate vaccines: optimizing global impact","volume":"4","author":"Terranella","year":"2011","journal-title":"Infect Drug Resist"},{"issue":"2","key":"10.1016\/j.jinf.2022.09.001_bib0008","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1080\/21645515.2018.1532248","article-title":"Recent changes in the epidemiology of Neisseria meningitidis serogroup W across the world, current vaccination policy choices and possible future strategies","volume":"15","author":"Booy","year":"2019","journal-title":"Hum Vaccin Immunother"},{"issue":"13","key":"10.1016\/j.jinf.2022.09.001_bib0009","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.vaccine.2016.02.014","article-title":"Global epidemiology of capsular group W meningococcal disease (1970-2015): Multifocal emergence and persistence of hypervirulent sequence type (ST)-11 clonal complex","volume":"34","author":"Mustapha","year":"2016","journal-title":"Vaccine"},{"issue":"2 Suppl","key":"10.1016\/j.jinf.2022.09.001_bib0010","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.jadohealth.2016.04.012","article-title":"The global evolution of meningococcal epidemiology following the introduction of meningococcal vaccines","volume":"59","author":"Pelton","year":"2016","journal-title":"J Adolesc Health"},{"key":"10.1016\/j.jinf.2022.09.001_bib0011","unstructured":"Dutch National Immunisation Programme: Meningococcal vaccine. Avaialble at: https:\/\/rijksvaccinatieprogramma.nl\/english (accessed 28 February, 2022)."},{"issue":"4","key":"10.1016\/j.jinf.2022.09.001_bib0012","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/14760584.2017.1258308","article-title":"The global meningococcal initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection","volume":"16","author":"Borrow","year":"2017","journal-title":"Expert Rev Vaccines"},{"issue":"28","key":"10.1016\/j.jinf.2022.09.001_bib0013","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES2015.20.28.21188","article-title":"Targeted vaccination of teenagers following continued rapid endemic expansion of a single meningococcal group W clone (sequence type 11 clonal complex), United Kingdom 2015","volume":"20","author":"Campbell","year":"2015","journal-title":"Eurosurveillance"},{"key":"10.1016\/j.jinf.2022.09.001_bib0014","unstructured":"GSK. Bexsero Summary of Product Characteristics. EMA, 2020. Available at: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/bexsero (accessed 28 February, 2022)."},{"key":"10.1016\/j.jinf.2022.09.001_bib0015","unstructured":"GSK. Bexsero Prescribing Information 2020. Available at: https:\/\/www.fda.gov\/media\/90996\/download (accessed 28 February, 2022)."},{"key":"10.1016\/j.jinf.2022.09.001_bib0016","unstructured":"Pfizer. Trumenba Summary of Product Characteristics. EMA, 2021. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/trumenba-epar-product-information_en.pdf (accessed 28 June, 2022)."},{"key":"10.1016\/j.jinf.2022.09.001_bib0017","unstructured":"Pfizer. Trumenba Prescribing Information, 2021. Available at: https:\/\/labeling.pfizer.com\/showlabeling.aspx?id=1796 (accessed 28 June, 2022)."},{"key":"10.1016\/j.jinf.2022.09.001_bib0018","unstructured":"Clinicaltrials.gov. NCT04502693. Study to assess effectiveness of GlaxoSmithKline's (GSK's) meningococcal Group B and combined ABCWY vaccines in healthy adolescents and young adults. Avaialble at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04502693 (accessed 28 February, 2022)."},{"issue":"1","key":"10.1016\/j.jinf.2022.09.001_bib0019","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1574-6976.2006.00053.x","article-title":"Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines","volume":"31","author":"Trotter","year":"2007","journal-title":"FEMS Microbiol Rev"},{"issue":"9911","key":"10.1016\/j.jinf.2022.09.001_bib0020","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(13)61612-8","article-title":"Effect of a serogroup a meningococcal conjugate vaccine (PsA\u2013TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study","volume":"383","author":"Daugla","year":"2014","journal-title":"Lancet North Am Ed"},{"issue":"3","key":"10.1016\/j.jinf.2022.09.001_bib0021","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/cid\/cis892","article-title":"Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity","volume":"56","author":"Kristiansen","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.jinf.2022.09.001_bib0022","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1080\/14760584.2018.1521280","article-title":"An update of clinical experience with the quadrivalent meningococcal ACWY-CRM conjugate vaccine","volume":"17","author":"Keshavan","year":"2018","journal-title":"Expert Rev Vaccines"},{"issue":"5","key":"10.1016\/j.jinf.2022.09.001_bib0023","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1086\/511646","article-title":"Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger","volume":"44","author":"Boisier","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.jinf.2022.09.001_bib0024","doi-asserted-by":"crossref","first-page":"944","DOI":"10.3201\/eid1306.070042","article-title":"Serogroup X in meningococcal disease, Western Kenya","volume":"13","author":"Materu","year":"2007","journal-title":"Emerg Infect Dis"},{"issue":"11","key":"10.1016\/j.jinf.2022.09.001_bib0025","doi-asserted-by":"crossref","first-page":"5146","DOI":"10.1128\/JCM.42.11.5146-5153.2004","article-title":"Distribution of serogroups and genotypes among disease-associated and carried isolates of Neisseria meningitidis from the Czech Republic, Greece, and Norway","volume":"42","author":"Yazdankhah","year":"2004","journal-title":"J Clin Microbiol"},{"issue":"5","key":"10.1016\/j.jinf.2022.09.001_bib0026","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.vaccine.2015.12.034","article-title":"A meningococcal NOMV-FHbp vaccine for Africa elicits broader serum bactericidal antibody responses against serogroup B and non-B strains than a licensed serogroup B vaccine","volume":"34","author":"Pajon","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.jinf.2022.09.001_bib0027","first-page":"1","article-title":"Meningococcal vaccination: recommendations of the advisory committee on immunization practices, United States, 2020","volume":"69","author":"Mbaeyi","year":"2020","journal-title":"Morb Mortal Wkly Rep (MMWR)"},{"issue":"8","key":"10.1016\/j.jinf.2022.09.001_bib0028","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1093\/cid\/cix993","article-title":"Current epidemiology and trends in meningococcal disease-United States, 1996-2015","volume":"66","author":"MacNeil","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.jinf.2022.09.001_bib0029","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/jamapediatrics.2020.1990","article-title":"Incidence of meningococcal disease before and after implementation of quadrivalent meningococcal conjugate vaccine in the United States","volume":"174","author":"Mbaeyi","year":"2020","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.jinf.2022.09.001_bib0030","unstructured":"Centers for Disease Control and Prevention. Meningococcal disease surveillance data tables. Avialable at: https:\/\/www.cdc.gov\/meningococcal\/surveillance\/surveillance-data.html#figure01 (accessed 28 February, 2022)."},{"key":"10.1016\/j.jinf.2022.09.001_bib0031","unstructured":"Centers for Disease Control and Prevention. Teen vaccination coverage publications and resources. Available at: https:\/\/www.cdc.gov\/vaccines\/imz-managers\/coverage\/teenvaxview\/pubs-presentations.html (accessed 28 February, 2022)."},{"key":"10.1016\/j.jinf.2022.09.001_bib0032","unstructured":"GSK. Menveo Prescribing Information 2020. Available at: https:\/\/gsksource.com\/pharma\/content\/dam\/GlaxoSmithKline\/US\/en\/Prescribing_Information\/Menveo\/pdf\/MENVEO.PDF (accessed 28 February, 2022)."},{"key":"10.1016\/j.jinf.2022.09.001_bib0033","unstructured":"GSK. Menveo Summary of Product Characteristics, EMA, 2020. Available at: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/menveo (accessed 28 February, 2022)."},{"key":"10.1016\/j.jinf.2022.09.001_bib0034","unstructured":"Argentina National Immunisation Calendar. Available at: https:\/\/bancos.salud.gob.ar\/sites\/default\/files\/2021-12\/calendario-nacional-vacunacion-2022.pdf (accessed 28 June, 2022)."},{"key":"10.1016\/j.jinf.2022.09.001_bib0035","unstructured":"CDC. Recommended child and adolescent immunization schedule for ages 18 years or younger, United States 2020. Available at: https:\/\/www.cdc.gov\/vaccines\/schedules\/hcp\/imz\/child-adolescent.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fschedules%2Fhcp%2Fchild-adolescent.html (accessed 28 June, 2022)."},{"key":"10.1016\/j.jinf.2022.09.001_bib0036","unstructured":"Public Health England. Routine vaccination schedule 2020. Available at: https:\/\/www.gov.uk\/government\/publications\/the-complete-routine-immunisation-schedule (accessed 28 February, 2022)."},{"key":"10.1016\/j.jinf.2022.09.001_bib0037","unstructured":"Switzerland: Federal Office of Public Health. Swiss Vaccination Schedule Synopsis. Available at: https:\/\/www.infovac.ch\/docs\/public\/-main\/synopsis-schweizerischer-impfplan-2020.pdf (accessed 28 February, 2022)."},{"issue":"8","key":"10.1016\/j.jinf.2022.09.001_bib0038","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.vaccine.2013.12.034","article-title":"Safety of a quadrivalent meningococcal serogroups A, C, W and Y conjugate vaccine (MenACWY-CRM) administered with routine infant vaccinations: results of an open-label, randomized, phase 3b controlled study in healthy infants","volume":"32","author":"Abdelnour","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.jinf.2022.09.001_sbref0039","series-title":"Proceedings of the European Society for Pediatric Infectious Diseases (ESPID) Annual Meeting","article-title":"Clinical and real-world evidence after a decade of meningococcal ACWY-CRM vaccine for prevention of invasive meningococcal disease in the pediatric population","author":"Ruiz Garcia","year":"2021"},{"issue":"12","key":"10.1016\/j.jinf.2022.09.001_bib0040","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1128\/CVI.00207-09","article-title":"Quadrivalent meningococcal vaccination of adults: phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, Menactra","volume":"16","author":"Reisinger","year":"2009","journal-title":"Clin Vaccine Immunol"},{"issue":"4","key":"10.1016\/j.jinf.2022.09.001_bib0041","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.vaccine.2019.11.015","article-title":"Effectiveness of a single dose of the quadrivalent meningococcal conjugate vaccine, MenACWY-CRM, in the Korean Armed Forces","volume":"38","author":"Im","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.jinf.2022.09.001_bib0042","unstructured":"Australian Government, Department of Health. Clinical update: National Immunisation Program (NIP) schedule changes from 1 July 2020 \u2013 advice for vaccination providers. Available at: https:\/\/www.health.gov.au\/news\/clinical-update-national-immunisation-program-nip-schedule-changes-from-1-july-2020-advice-for-vaccination-providers (accessed 28 February, 2022)."},{"key":"10.1016\/j.jinf.2022.09.001_bib0043","unstructured":"Government of Canada: Recommended immunization schedules: Canadian Immunization Guide. Available at: https:\/\/www.canada.ca\/en\/public-health\/services\/publications\/healthy-living\/canadian-immunization-guide-part-1-key-immunization-information\/page-13-recommended-immunization-schedules.html #p1c12a2 (accessed 28 June, 2022)."},{"key":"10.1016\/j.jinf.2022.09.001_bib0044","unstructured":"GSK Press Release, 23 January 2020. World's first meningitis B national infant vaccination programme shows 75% drop in cases over three years. Available at: https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/world-s-first-meningitis-b-national-infant-vaccination-programme-shows-75-drop-in-cases-over-three-years\/ (accessed 28 February, 2022)."},{"issue":"6","key":"10.1016\/j.jinf.2022.09.001_bib0045","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jinf.2020.07.034","article-title":"Methods to evaluate serogroup B meningococcal vaccines: from predictions to real-world evidence","volume":"81","author":"Borrow","year":"2020","journal-title":"J Infect"},{"issue":"1","key":"10.1016\/j.jinf.2022.09.001_bib0046","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.02161-20","article-title":"Meningococcal deduced vaccine antigen reactivity (MenDeVAR) index: a rapid and accessible tool that exploits genomic data in public health and clinical microbiology applications","volume":"59","author":"Rodrigues","year":"2020","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jinf.2022.09.001_bib0047","unstructured":"ECDC Vaccine Scheduler. Meningococcal disease: Recommended vaccinations. Available at: https:\/\/vaccine-schedule.ecdc.europa.eu\/Scheduler\/ByDisease?SelectedDiseaseId=48&SelectedCountryIdByDisease=-1 (accessed 28 February, 2022)."},{"issue":"1","key":"10.1016\/j.jinf.2022.09.001_bib0048","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jinf.2021.04.031","article-title":"Recent advances in meningococcal B disease prevention: real-world evidence from 4CMenB vaccination","volume":"83","author":"Martinon-Torres","year":"2021","journal-title":"J Infect"},{"key":"10.1016\/j.jinf.2022.09.001_bib0049","unstructured":"Government of South Australia. SA Health. Meningococcal B Immunisation Program. Available at: https:\/\/www.sahealth.sa.gov.au\/wps\/wcm\/connect\/public+content\/sa+health+internet\/conditions\/immunisation\/immunisation+programs\/meningococcal+b+immunisation+program (accessed 28 February, 2022)."},{"issue":"1","key":"10.1016\/j.jinf.2022.09.001_bib0050","first-page":"52","article-title":"[Immunisation schedule of the Spanish association of paediatrics: 2020 recommendations]","volume":"92","author":"Alvarez Garcia","year":"2020","journal-title":"An Pediatr (Engl Ed)"},{"key":"10.1016\/j.jinf.2022.09.001_bib0051","unstructured":"Haute Autorite de Sante (HAS). Vaccination strategy for the prevention of invasive meningococcal infections: Serogroup B and the place of Bexsero. https:\/\/www.has-sante.fr\/jcms\/p_3066921\/fr\/strategie-de-vaccination-pour-la-prevention-des-infections-invasives-a-meningocoques-le-serogroupe-b-et-la-place-de-bexser (accessed 28 February, 2022)."},{"issue":"7","key":"10.1016\/j.jinf.2022.09.001_bib0052","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S1473-3099(17)30170-6","article-title":"Meningococcal serogroup B strain coverage of the multicomponent 4CMenB vaccine with corresponding regional distribution and clinical characteristics in England, Wales, and Northern Ireland, 2007-08 and 2014-15: a qualitative and quantitative assessment","volume":"17","author":"Parikh","year":"2017","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.jinf.2022.09.001_bib0053","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1056\/NEJMoa1901229","article-title":"Vaccination of Infants with meningococcal group B vaccine (4CMenB) in England","volume":"382","author":"Ladhani","year":"2020","journal-title":"N Engl J Med"},{"issue":"10061","key":"10.1016\/j.jinf.2022.09.001_bib0054","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1016\/S0140-6736(16)31921-3","article-title":"Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study","volume":"388","author":"Parikh","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jinf.2022.09.001_bib0055","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines8030469","article-title":"Effectiveness and impact of the 4CMenB vaccine against group B meningococcal disease in two italian regions using different vaccination schedules: a five-year retrospective observational study (2014-2018)","volume":"8","author":"Azzari","year":"2020","journal-title":"Vaccines"},{"issue":"21","key":"10.1016\/j.jinf.2022.09.001_bib0056","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1001\/jama.2020.20449","article-title":"Association of use of a meningococcus group B vaccine with group B invasive meningococcal disease among children in Portugal","volume":"324","author":"Rodrigues","year":"2020","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.jinf.2022.09.001_bib0057","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1093\/cid\/cix154","article-title":"Impact of an immunization campaign to control an increased incidence of serogroup b meningococcal disease in one region of Quebec, Canada","volume":"64","author":"De Wals","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.jinf.2022.09.001_bib0058","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41541-021-00388-3","article-title":"Looking beyond meningococcal B with the 4CMenB vaccine: the Neisseria effect","volume":"6","author":"Ruiz Garcia","year":"2021","journal-title":"NPJ Vaccines"},{"issue":"50","key":"10.1016\/j.jinf.2022.09.001_bib0059","doi-asserted-by":"crossref","first-page":"7419","DOI":"10.1016\/j.vaccine.2018.02.081","article-title":"Biological feasibility and importance of a gonorrhea vaccine for global public health","volume":"37","author":"Vincent","year":"2019","journal-title":"Vaccine"},{"issue":"Suppl 1","key":"10.1016\/j.jinf.2022.09.001_bib0060","doi-asserted-by":"crossref","first-page":"S734","DOI":"10.1093\/ofid\/ofx180.002","article-title":"Possible impacts of wide-scale vaccination against serogroup B Neisseria meningitiditis on gonorrhoea incidence rates in one region of Quebec, Canada","volume":"4","author":"Longtin","year":"2017","journal-title":"Open Forum Infect Dis"},{"issue":"5","key":"10.1016\/j.jinf.2022.09.001_bib0061","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1080\/21645515.2017.1381810","article-title":"Impact of meningococcal group B OMV vaccines, beyond their brief","volume":"14","author":"Petousis-Harris","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.jinf.2022.09.001_bib0062","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(21)00812-4","article-title":"Effectiveness of a serogroup B outer membrane vesicle meningococcal vaccine against gonorrhoea: a retrospective observational study","author":"Abara","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jinf.2022.09.001_bib0063","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(21)00754-4","article-title":"Effectiveness and impact of the 4CMenB vaccine against invasive serogroup B meningococcal disease and gonorrhoea in an infant, child, and adolescent programme: an observational cohort and case-control study","author":"Wang","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jinf.2022.09.001_bib0064","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(21)00744-1","article-title":"Public health impact and cost-effectiveness of gonorrhoea vaccination: an integrated transmission-dynamic health-economic modelling analysis","author":"Whittles","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"10.1016\/j.jinf.2022.09.001_bib0065","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1080\/21645515.2018.1425659","article-title":"Safety and immunogenicity of a meningococcal B recombinant vaccine when administered with routine vaccines to healthy infants in Taiwan: A phase 3, open-label, randomized study","volume":"14","author":"Chiu","year":"2018","journal-title":"Hum Vaccin Immunother"},{"issue":"6","key":"10.1016\/j.jinf.2022.09.001_bib0066","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1001\/jama.2012.85","article-title":"Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial","volume":"307","author":"Gossger","year":"2012","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.jinf.2022.09.001_bib0067","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S2352-4642(18)30103-2","article-title":"Safety of multicomponent meningococcal group B vaccine (4CMenB) in routine infant immunisation in the UK: a prospective surveillance study","volume":"2","author":"Bryan","year":"2018","journal-title":"Lancet Child Adolesc Health"},{"issue":"22","key":"10.1016\/j.jinf.2022.09.001_bib0068","first-page":"608","article-title":"Use of serogroup B meningococcal vaccines in persons aged \u226510 years at increased risk for serogroup B meningococcal disease: recommendations of the advisory committee on immunization practices","volume":"64","author":"Folaranmi","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"4","key":"10.1016\/j.jinf.2022.09.001_bib0069","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.vaccine.2018.11.078","article-title":"Parental awareness of Meningococcal B vaccines and willingness to vaccinate their teens","volume":"37","author":"Basta","year":"2019","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.jinf.2022.09.001_bib0070","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2018-0344","article-title":"Adoption of serogroup B meningococcal vaccine recommendations","volume":"142","author":"Kempe","year":"2018","journal-title":"Pediatrics"},{"issue":"8","key":"10.1016\/j.jinf.2022.09.001_bib0071","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1080\/21645515.2017.1313940","article-title":"Meningococcal serogroup B vaccine: knowledge and acceptability among parents in Italy","volume":"13","author":"Morrone","year":"2017","journal-title":"Hum Vaccin Immunother"},{"issue":"2","key":"10.1016\/j.jinf.2022.09.001_bib0072","first-page":"E147","article-title":"Do HCWs adequately know about meningitis and 4CMenB vaccine and recommend its use to parents? A cross sectional analysis in Campania Region, Italy","volume":"60","author":"Ponticelli","year":"2019","journal-title":"J Prev Med Hyg"},{"key":"10.1016\/j.jinf.2022.09.001_bib0073","unstructured":"Centers for Disease Control and Prevention. Group settings as a risk factor. https:\/\/www.cdc.gov\/meningococcal\/about\/risk-community.html (accessed 28 February, 2022)."},{"key":"10.1016\/j.jinf.2022.09.001_bib0074","doi-asserted-by":"crossref","DOI":"10.1097\/INF.0000000000003455","article-title":"A real-world claims data analysis of meningococcal serogroup B vaccine series completion and potential missed opportunities in the United States","author":"Packnett","year":"2022","journal-title":"Pediatr Infect Dis J"},{"issue":"39","key":"10.1016\/j.jinf.2022.09.001_bib0075","doi-asserted-by":"crossref","first-page":"5899","DOI":"10.1016\/j.vaccine.2019.06.065","article-title":"Meningococcal-group B (MenB) vaccine series completion and adherence to dosing schedule in the United States: a retrospective analysis by vaccine and payer type","volume":"37","author":"Packnett","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.jinf.2022.09.001_bib0076","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s12889-016-2845-z","article-title":"Factors influencing completion of multi-dose vaccine schedules in adolescents: a systematic review","volume":"16","author":"Gallagher","year":"2016","journal-title":"BMC Public Health"},{"issue":"1","key":"10.1016\/j.jinf.2022.09.001_bib0077","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1071\/SH06008","article-title":"Predictors of completion of a hepatitis B vaccination schedule in attendees at a primary health care centre","volume":"4","author":"Macdonald","year":"2007","journal-title":"Sex Health"},{"issue":"47","key":"10.1016\/j.jinf.2022.09.001_bib0078","doi-asserted-by":"crossref","first-page":"7558","DOI":"10.1016\/j.vaccine.2020.08.007","article-title":"Modelling the impact of 4CMenB and MenACWY meningococcal combined vaccination strategies including potential 4CMenB cross-protection: an application to England","volume":"38","author":"Beck","year":"2020","journal-title":"Vaccine"},{"issue":"36","key":"10.1016\/j.jinf.2022.09.001_bib0079","doi-asserted-by":"crossref","first-page":"5485","DOI":"10.1016\/j.vaccine.2017.06.063","article-title":"New perspectives for hexavalent vaccines","volume":"36","author":"Obando-Pacheco","year":"2018","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.jinf.2022.09.001_bib0080","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1080\/21645515.2015.1044180","article-title":"The value of childhood combination vaccines: from beliefs to evidence","volume":"11","author":"Maman","year":"2015","journal-title":"Hum Vaccin Immunother"},{"issue":"Suppl 1","key":"10.1016\/j.jinf.2022.09.001_bib0081","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/S0264-410X(01)00299-7","article-title":"Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story","volume":"20","author":"Miller","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.jinf.2022.09.001_bib0082","unstructured":"Centers for Disease Control and Prevention. Health, United States, 2018 - Data Finder. Available at: https:\/\/www.cdc.gov\/nchs\/hus\/contents2018.htm#Table_032 (accessed 28 February, 2022)."},{"issue":"1","key":"10.1016\/j.jinf.2022.09.001_bib0083","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1080\/21645515.2019.1632679","article-title":"Determinants of meningococcal ACWY vaccination in adolescents in the US: completion and compliance with the CDC recommendations","volume":"16","author":"Cheng","year":"2020","journal-title":"Hum Vaccin Immunother"},{"issue":"33","key":"10.1016\/j.jinf.2022.09.001_bib0084","doi-asserted-by":"crossref","first-page":"718","DOI":"10.15585\/mmwr.mm6833a2","article-title":"National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years - United States, 2018","volume":"68","author":"Walker","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jinf.2022.09.001_bib0085","first-page":"1","article-title":"Potential public health impact of a Neisseria meningitidis A, B, C, W, and Y pentavalent vaccine in the United States","author":"Huang","year":"2021","journal-title":"Postgrad Med"},{"issue":"4","key":"10.1016\/j.jinf.2022.09.001_bib0086","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1080\/21645515.2019.1682845","article-title":"Disparities in healthcare providers' interpretations and implementations of ACIP's meningococcal vaccine recommendations","volume":"16","author":"Huang","year":"2020","journal-title":"Hum Vaccin Immunother"},{"issue":"33","key":"10.1016\/j.jinf.2022.09.001_bib0087","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.15585\/mmwr.mm6933a1","article-title":"National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 Years - United States, 2019","volume":"69","author":"Elam-Evans","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"46","key":"10.1016\/j.jinf.2022.09.001_bib0088","doi-asserted-by":"crossref","first-page":"7350","DOI":"10.1016\/j.vaccine.2020.09.035","article-title":"Serogroup B meningococcal vaccination practice patterns on college campuses","volume":"38","author":"Haimowitz","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.jinf.2022.09.001_bib0089","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2021.03.071","article-title":"Meningococcal B vaccination coverage among older adolescents in the United States","author":"La","year":"2021","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.jinf.2022.09.001_bib0090","first-page":"e440","article-title":"Impact of MMRV combination vaccine on childhood vaccination compliance","volume":"18","author":"Ackerson","year":"2012","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.jinf.2022.09.001_bib0091","article-title":"Impact of combination MMRV vaccine on first-dose coverage for measles and varicella: a population-based study","author":"MacDonald","year":"2020","journal-title":"J Public Health"},{"issue":"3","key":"10.1016\/j.jinf.2022.09.001_bib0092","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.respe.2015.12.019","article-title":"Public health impact of Infanrix hexa (DTPa-HBV-IPV\/Hib) reimbursement: a study programme in France. Part 2: evolution of the acceptability of infants' vaccination against hepatitis B in general and pediatric practices - the PRALINE study","volume":"64","author":"Vie le Sage","year":"2016","journal-title":"Rev Epidemiol Sante Publique"},{"issue":"5","key":"10.1016\/j.jinf.2022.09.001_bib0093","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2017-0001","article-title":"Immunization, antibiotic use, and pneumococcal colonization over a 15-year period","volume":"140","author":"Lee","year":"2017","journal-title":"Pediatrics"},{"issue":"21","key":"10.1016\/j.jinf.2022.09.001_bib0094","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1016\/j.vaccine.2015.03.001","article-title":"A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: results of a phase 2 randomized, controlled trial","volume":"33","author":"Block","year":"2015","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.jinf.2022.09.001_bib0095","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1080\/21645515.2015.1029686","article-title":"Immunogenicity and safety of investigational vaccine formulations against meningococcal serogroups A, B, C, W, and Y in healthy adolescents","volume":"11","author":"Saez-Llorens","year":"2015","journal-title":"Hum Vaccin Immunother"},{"issue":"5","key":"10.1016\/j.jinf.2022.09.001_bib0096","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1080\/21645515.2018.1457595","article-title":"Four-year antibody persistence and response to a booster dose of a pentavalent MenABCWY vaccine administered to healthy adolescents and young adults","volume":"14","author":"Saez-Llorens","year":"2018","journal-title":"Hum Vaccin Immunother"},{"issue":"35","key":"10.1016\/j.jinf.2022.09.001_bib0097","doi-asserted-by":"crossref","first-page":"5309","DOI":"10.1016\/j.vaccine.2018.07.016","article-title":"Breadth of coverage against a panel of 110 invasive disease isolates, immunogenicity and safety for 2 and 3 doses of an investigational MenABCWY vaccine in US adolescents - Results from a randomized, controlled, observer-blind phase II study","volume":"36","author":"Welsch","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.jinf.2022.09.001_bib0098","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(22)00002-0","article-title":"Is the end of gonorrhoea in sight?","author":"Ong","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jinf.2022.09.001_bib0099","unstructured":"World Health Organisation Initiatives. Defeating meningitis by 2030: A global road map. Available at: https:\/\/www.who.int\/publications\/m\/item\/defeating-meningitis-by-2030-a-global-road-map (accessed 28 February, 2022)."},{"issue":"1","key":"10.1016\/j.jinf.2022.09.001_bib0100","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1186\/s12889-020-09181-8","article-title":"Parental awareness and utilization of meningococcal serogroup B vaccines in the United States","volume":"20","author":"Srivastava","year":"2020","journal-title":"BMC Public Health"},{"issue":"27","key":"10.1016\/j.jinf.2022.09.001_bib0101","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1016\/j.vaccine.2013.04.036","article-title":"Emergence of serogroup X meningococcal disease in Africa: need for a vaccine","volume":"31","author":"Xie","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.jinf.2022.09.001_bib0102","doi-asserted-by":"crossref","first-page":"751","DOI":"10.3389\/fimmu.2019.00751","article-title":"The development of a vaccine against meningococcus B using reverse vaccinology","volume":"10","author":"Masignani","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jinf.2022.09.001_bib0103","unstructured":"Ireland National Immunisation Office. Immunisation schedule. Available at: https:\/\/www.hse.ie\/eng\/health\/immunisation\/pubinfo\/pcischedule\/immschedule\/ (accessed 28 February, 2022)."},{"key":"10.1016\/j.jinf.2022.09.001_bib0104","unstructured":"Italy Ministry of Health. Piano Nazionale Prevenzione Vaccinale, PNPV 2017-2019. Available at: https:\/\/www.salute.gov.it\/imgs\/C_17_pubblicazioni_2571_allegato.pdf (accessed 28 February, 2022)."},{"key":"10.1016\/j.jinf.2022.09.001_bib0105","unstructured":"Ministry of Health of the Republic of Lithuania. Official: children in Lithuania will be vaccinated against type B meningococcus. Available at: https:\/\/sam.lrv.lt\/en\/news\/minister-of-health-aurelijus-veryga-signed-an-order-by-which-vaccines-against-type-b-meningococcus-are-to-be-included-in-the-schedule-for-the-preventive-vaccination-of-children-the-start-of-the-vaccination-is-scheduled-as-of-july-this-year (accessed 28 February, 2022)."},{"key":"10.1016\/j.jinf.2022.09.001_bib0106","unstructured":"Government of Malta. National immunisation schedule. Available at: https:\/\/deputyprimeminister.gov.mt\/en\/phc\/pchyhi\/Pages\/National-Immunisation-Schedule.aspx (February 28, 2022)."},{"key":"10.1016\/j.jinf.2022.09.001_bib0107","unstructured":"SA\u00daDE. Gabinete do Secret\u00e1rio de Estado da Sa\u00fade. Despacho n.\u00b0 12434\/2019. Available at: https:\/\/dre.pt\/application\/conteudo\/127608823 (accessed 28 February, 2022)."},{"issue":"31","key":"10.1016\/j.jinf.2022.09.001_bib0108","doi-asserted-by":"crossref","first-page":"4243","DOI":"10.1016\/j.vaccine.2019.06.021","article-title":"Impact of a mass vaccination campaign against Serogroup B meningococcal disease in the Saguenay-Lac-Saint-Jean region of Quebec four years after its launch","volume":"37","author":"Deceuninck","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.jinf.2022.09.001_bib0109","doi-asserted-by":"crossref","first-page":"e1661","DOI":"10.1093\/cid\/ciaa1244","article-title":"First real world evidence of meningococcal group B vaccine, 4CMenB, protection against meningococcal group W disease; prospective enhanced national surveillance, England","volume":"73","author":"Ladhani","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"24","key":"10.1016\/j.jinf.2022.09.001_bib0110","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1016\/j.vaccine.2021.02.065","article-title":"Post-licensure observational safety study after meningococcal B vaccine 4CMenB (Bexsero) vaccination within the routine UK immunisation program","volume":"39","author":"Hall","year":"2021","journal-title":"Vaccine"},{"issue":"32","key":"10.1016\/j.jinf.2022.09.001_bib0111","doi-asserted-by":"crossref","first-page":"4935","DOI":"10.1016\/j.vaccine.2020.05.089","article-title":"The risk of Kawasaki disease after pneumococcal conjugate & meningococcal B vaccine in England: a self-controlled case-series analysis","volume":"38","author":"Stowe","year":"2020","journal-title":"Vaccine"},{"issue":"17","key":"10.1016\/j.jinf.2022.09.001_bib0112","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2018.23.17.17-00468","article-title":"Adverse events following immunisation with a meningococcal serogroup B vaccine: report from post-marketing surveillance, Germany, 2013 to 2016","volume":"23","author":"Mentzer","year":"2018","journal-title":"Euro Surveill"},{"issue":"9960","key":"10.1016\/j.jinf.2022.09.001_bib0113","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/S0140-6736(14)60842-4","article-title":"Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial","volume":"384","author":"Read","year":"2014","journal-title":"Lancet"},{"issue":"42","key":"10.1016\/j.jinf.2022.09.001_bib0114","doi-asserted-by":"crossref","first-page":"6171","DOI":"10.1016\/j.vaccine.2019.08.065","article-title":"MenACWY-CRM conjugate vaccine booster dose given 4\u20136\u00a0years after priming: Results from a phase IIIb, multicenter, open label study in adolescents and adults","volume":"37","author":"Tipton","year":"2019","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.jinf.2022.09.001_bib0115","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1080\/21645515.2019.1670125","article-title":"Results from a large post-marketing safety surveillance study in the Republic of Korea with a quadrivalent meningococcal CRM-conjugate vaccine in individuals aged 2 months-55 years","volume":"16","author":"Yoo","year":"2020","journal-title":"Hum Vaccin Immunother"}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445322005308?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445322005308?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T21:35:30Z","timestamp":1759008930000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445322005308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":115,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S0163445322005308"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2022.09.001","relation":{},"ISSN":["0163-4453"],"issn-type":[{"value":"0163-4453","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Public health perspective of a pentavalent meningococcal vaccine combining antigens of MenACWY-CRM and 4CMenB","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2022.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd on behalf of The British Infection Association.","name":"copyright","label":"Copyright"}]}}